The price of a prescription drug is not a single number. It is a system — a stack of prices, discounts, rebates, and benefit design rules that produces a different out-of-pocket figure depending on who is buying, through what channel, with what coverage, and at which pharmacy. For patients with comprehensive insurance and low cost-sharing, much of this complexity is invisible. For patients without insurance or with coverage that leaves them responsible for a substantial share of drug costs, it determines whether a prescribed medication is affordable.
The Pricing Stack: List Price to Cash Price
Several distinct price points are relevant in the U.S. pharmaceutical market, and they are often confused in public discussion.
Wholesale Acquisition Cost (WAC): The WAC is the list price set by the manufacturer for drugs sold to wholesalers and direct purchasers. It is the baseline price before any discounts, rebates, or markups are applied. WAC is set by the manufacturer and is publicly reported. As SmithRx explains, WAC represents the manufacturer’s stated price to the supply chain before the commercial negotiation layer begins.
Average Wholesale Price (AWP): The AWP is a benchmark derived from WAC — traditionally calculated as WAC plus 20 percent. It is a published price used in insurance contracting and reimbursement calculations, not a price at which most transactions actually occur. Despite its name, the AWP has long been understood to overstate the prices at which drugs are actually purchased by pharmacies. It has been called a “sticker price” that functions as a benchmark for contracting rather than a reflection of actual acquisition costs.
Negotiated price: The price an insurer or pharmacy benefit manager (PBM) has negotiated with the manufacturer, net of rebates — this is what a plan actually pays for a drug, though members may never see this figure.
Cash price: What an uninsured patient (or an insured patient who chooses not to use insurance) pays at the pharmacy. Cash prices can vary enormously across pharmacies for the same drug, often without any obvious logic. A drug might cost $200 at one chain pharmacy and $15 at a warehouse club pharmacy or through a discount card. Cash prices are not directly tied to AWP, WAC, or negotiated prices in any consistent way.
National Average Drug Acquisition Cost (NADAC): The CMS publishes NADAC data based on surveys of actual invoice prices paid by retail community pharmacies — a more accurate benchmark for pharmacy acquisition costs than AWP. But NADAC is not consistently used in patient-facing pricing.
What Happens at the Pharmacy Counter Without Insurance
A patient without insurance who presents a prescription at a retail pharmacy is typically quoted the pharmacy’s “usual and customary” (U&C) price, which may approximate the AWP or some internal pricing formula — not a negotiated or discounted rate. Retail U&C prices tend to be among the highest prices in the system, substantially above what insurers or PBMs pay.
For generic drugs, cash prices have become substantially more competitive as programs like GoodRx, manufacturer generics, and warehouse club pharmacy programs have emerged. For brand-name drugs, however, the cash price at a retail pharmacy can approach the full list price, which for specialty drugs may be thousands of dollars per month.
GoodRx and Discount Card Mechanics
Discount programs like GoodRx are not insurance. They are PBM-negotiated group pricing programs extended to individual consumers. GoodRx and similar services contract with pharmacy benefit managers who have negotiated discount rates with retail pharmacies. When a patient presents a GoodRx code, the pharmacy processes the claim as if the patient were part of a group contracting arrangement, triggering the pre-negotiated price.
The prices available through discount cards can be substantially lower than cash prices — sometimes dramatically so for generic drugs — but they vary by drug, pharmacy, and region. For generics, discount card prices can be a few dollars for a month’s supply. For brand-name drugs, discount cards typically provide smaller reductions and may still leave patients facing prices of hundreds or thousands of dollars per month. Importantly, amounts paid through discount cards generally do not count toward a patient’s insurance deductible or out-of-pocket maximum — meaning a patient using a discount card is, from the insurer’s accounting perspective, an uninsured purchaser.
Manufacturer Patient Assistance Programs
Most major pharmaceutical manufacturers operate Patient Assistance Programs (PAPs) that provide their drugs at reduced or no cost to patients who meet eligibility requirements. These programs typically require patients to demonstrate financial need (often based on income relative to the federal poverty level), lack of adequate insurance coverage for the drug in question, and U.S. residency.
The limitations of PAPs are well-documented. Application processes can be complex and time-consuming, requiring physician involvement and regular recertification. Eligibility thresholds vary by manufacturer and program and may exclude patients with modest incomes who nonetheless cannot afford high drug costs. Programs typically do not cover patients who have any insurance coverage for the drug in question — a significant limitation for patients with insurance that covers a drug but with high cost-sharing.
Coverage gaps in PAPs have been documented extensively. Patients who fall just above income thresholds, patients with insurance that covers the drug at an unaffordable co-pay, patients with limited English proficiency or difficulty navigating application systems, and patients whose physicians lack staff capacity to administer the application process are all groups for whom PAPs regularly fail to deliver consistent access.
The 340B Drug Discount Program
The 340B Drug Discount Program, created in 1992, requires pharmaceutical manufacturers who participate in Medicaid to sell covered outpatient drugs at ceiling prices (substantially below WAC) to certain categories of covered entities — safety-net providers serving high proportions of low-income and uninsured patients. Eligible entities include disproportionate share hospitals, federally qualified health centers, Ryan White HIV/AIDS clinics, and certain rural hospitals, among others.
As 340B Health documents, the program was designed to allow safety-net providers to stretch limited federal resources, using savings from discounted drug purchases to provide additional services or subsidize care for uninsured patients. The discounts are substantial — typically 25 to 50 percent below WAC.
The 340B program is controversial in several respects. Critics argue that many covered entities — particularly large hospital systems — use 340B discounts to generate revenue rather than to directly reduce drug costs for low-income patients. Patients receiving care at a 340B-covered entity do not automatically pay 340B prices at the pharmacy counter. Whether 340B savings flow to patients or to the covered entity’s operating budget depends on the entity’s policies. The program’s eligibility requirements, administration, and revenue use practices have been subjects of ongoing legislative and regulatory scrutiny.
Copay Accumulator Programs
Insured patients facing high cost-sharing for brand-name drugs have historically used manufacturer copay assistance cards or coupons to reduce their out-of-pocket costs. These programs typically provide a fixed annual dollar amount — sometimes thousands of dollars — to cover copays and coinsurance.
Beginning in the mid-2010s, insurance plans began implementing “copay accumulator” programs that alter how manufacturer assistance counts toward a patient’s cost-sharing obligations. Under a standard accumulator design, the amounts paid by the manufacturer coupon do not count toward the patient’s deductible or out-of-pocket maximum. As KFF explains, a copay adjustment program allows enrollees to use manufacturer coupons at the point of sale, while ensuring that only amounts paid by the patient count toward their cost-sharing obligations.
The practical consequence: a patient using a $5,000 manufacturer coupon toward a drug with $10,000 in annual cost-sharing receives the benefit of reduced immediate out-of-pocket costs only while the coupon funds last. Once the coupon value is exhausted, the patient faces the full remaining cost-sharing obligation, often mid-year and without warning. When a patient reaches that point before having accumulated enough cost-sharing to enter catastrophic coverage, the effect is a sudden and sharp increase in out-of-pocket burden.
The National Conference of State Legislatures notes that several states have enacted laws restricting copay accumulator programs, particularly for drugs without generic alternatives. A 2023 federal regulation initially addressed accumulator programs in ACA-compliant plans, though the regulatory landscape has continued to evolve.
A related practice, the “copay maximizer,” is designed to extract the maximum value from a manufacturer coupon without allowing it to accelerate a patient’s path to catastrophic coverage. Under a maximizer design, the annual coupon value is spread evenly over the benefit year, keeping the patient perpetually in the cost-sharing zone rather than accelerating them into catastrophic coverage.
The Gap Between Programs and Patients
The programs described above — PAPs, 340B pricing, discount cards, copay assistance — constitute a patchwork through which patients with limited resources attempt to access drugs priced well beyond their means. The gaps in that patchwork are structural. A patient who is slightly over income thresholds for PAPs, who is insured but faces high cost-sharing, who does not receive care at a 340B-covered entity, and whose insurer uses an accumulator program may fall through every layer.
Research on cost-related non-adherence — patients who do not fill prescriptions, skip doses, or take less than prescribed because of cost — consistently finds rates of 10 to 20 percent among the general adult population and higher among patients with chronic conditions or limited incomes. The consequences of non-adherence are documented across therapeutic areas: poorer disease control, higher rates of acute events, and increased utilization of emergency and inpatient care.
The complexity of the discount and assistance ecosystem means that access to affordable drugs is not a function of drug prices alone. It is also a function of which programs a patient knows about, which their providers can help them access, and which their insurance benefit design permits them to use effectively.
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.